According to DataM Intelligence, the U.S. Ophthalmology Amniotic Membrane Market was valued at approximately USD 3.13 billion in 2024 and is projected to reach USD 7.35 billion by 2033, growing at a compound annual growth rate (CAGR) of 9.4% during the forecast period from 2025 to 2033. This growth is largely driven by the rising prevalence of ocular disorders, technological advancements in surgical procedures, and increased awareness of regenerative medicine applications in eye care. Amniotic membrane products are widely used in ophthalmology due to their anti-inflammatory, anti-fibrotic, and regenerative properties that make them ideal for treating complex ocular surface diseases.

The market is witnessing significant growth due to the increasing number of ophthalmic surgeries, expanding patient pool, and improved healthcare infrastructure in the U.S. Hospitals and specialized eye care centers are adopting amniotic membrane grafts as a standard treatment for persistent epithelial defects, corneal ulcers, and pterygium surgeries. The United States remains the largest market within North America due to the advanced medical ecosystem, high healthcare spending, and the presence of leading market players. The growing trend toward personalized medicine and tissue engineering is also accelerating the adoption of these advanced biologic treatments.

𝗚𝗲𝘁 𝗮 𝗦𝗮𝗺𝗽𝗹𝗲 𝗣𝗗𝗙 𝗕𝗿𝗼𝗰𝗵𝘂𝗿𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗥𝗲𝗽𝗼𝗿𝘁 (𝗨𝘀𝗲 𝗖𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗲 𝗘𝗺𝗮𝗶𝗹 𝗜𝗗 𝗳𝗼𝗿 𝗮 𝗤𝘂𝗶𝗰𝗸 𝗥𝗲𝘀𝗽𝗼𝗻𝘀𝗲): https://www.datamintelligence.com/download-sample/us-ophthalmology-amniotic-membrane-market?jd

Market Segmentation

By Product Type (Cryopreserved Amniotic Membrane, Lyophilization Amniotic Membrane, Dehydrated Amniotic Membrane)
By Application (Ophthalmology, Surgical Wounds, Others)
By End-User (Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Clinics, Others)

Market Share

Regionally, the United States holds a commanding share of the ophthalmology amniotic membrane market due to its well-established healthcare infrastructure, extensive network of hospitals and ophthalmic clinics, and high adoption of advanced medical technologies. The availability of skilled ophthalmologists, coupled with government initiatives supporting research and development in regenerative medicine, makes the U.S. a leader in this market.

Hospitals dominate the end-user segment, accounting for the largest share of product consumption, as they are primary centers for ocular surgeries and post-surgical care requiring amniotic membrane grafts. Ambulatory surgical centers and specialized ophthalmic clinics follow closely, driven by the rising number of outpatient surgeries and outpatient care adoption trends.

The cryopreserved amniotic membrane segment holds the largest market share in product type, favored for its preserved biological properties that promote better healing and tissue regeneration. In terms of applications, dry eye disease and corneal ulcers represent the largest segments, as these conditions are highly prevalent and require advanced regenerative solutions for effective management.

Market Drivers

The U.S. ophthalmology amniotic membrane market is primarily driven by the increasing prevalence of ocular surface disorders such as dry eye disease, corneal ulcers, and persistent epithelial defects. The Centers for Disease Control and Prevention (CDC) reports millions of cases annually in the U.S., prompting higher demand for effective treatments.

Advancements in drug and surgical therapies, including long-acting formulations of amniotic membranes and minimally invasive surgical procedures, are significant growth catalysts. The regenerative properties of the amniotic membrane promote faster healing, reduce inflammation, and prevent scarring, which are critical in managing complex ocular conditions.

Another key driver is the growing awareness among patients and healthcare providers regarding the benefits of early diagnosis and treatment. Various patient education programs and healthcare initiatives have improved access to advanced ophthalmic treatments, further accelerating market growth.

Additionally, the shift toward digital health solutions is boosting market demand. Mobile apps and online platforms now help monitor treatment adherence, provide symptom tracking, and facilitate teleconsultations, enhancing the overall management of ocular diseases.

Key Players

The U.S. ophthalmology amniotic membrane market includes several prominent players:

• BioTissue, Inc.
• Corza Ophthalmology
• Integra LifeSciences
• Merakris Therapeutics
• Seed Biotech
• Atlas Ocular
• BioLab Holdings
• Orthofix Medical
• Labtician Ophthalmics
• Smith & Nephew

These industry leaders focus on continuous product development, strategic partnerships, and expanding distribution networks across the U.S. to meet growing patient and healthcare provider demands for high-quality regenerative products.

Recent Developments

In February 2025, the U.S. FDA approved a next-generation dehydrated amniotic membrane product designed for faster application and longer shelf life, enhancing treatment efficiency in ophthalmic clinics and hospitals.

In July 2025, BioTissue, Inc. launched a novel cryopreserved amniotic membrane platform optimized for managing severe dry eye disease, aimed at improving patient compliance and clinical outcomes.

Conclusion

The U.S. ophthalmology amniotic membrane market is on a robust growth trajectory, driven by the rising incidence of ocular disorders, advances in regenerative medicine, and expanding healthcare infrastructure. Cryopreserved amniotic membrane remains the leading product type due to its superior biological properties. Hospitals dominate the end-user segment, while dry eye disease and corneal ulcers represent the largest application areas.

The market is further supported by growing patient awareness, government initiatives, and technological innovations, including the integration of digital health tools and long-acting formulations. With continuous R&D and new product launches, the U.S. ophthalmology amniotic membrane market is expected to deliver sustained growth through 2033, improving therapeutic outcomes and patient quality of life.

About DataM Intelligence

DataM Intelligence is a Market Research and Consulting firm providing end-to-end business solutions from Research to Consulting. Their research database features over 6300 reports across 40+ domains, serving more than 200 companies in 50+ countries.

Contact Us:
Company: DataM Intelligence 4Market Research LLP
Contact: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com